DelveInsight’s, “Allergic Rhinitis Pipeline Insight, 2023,” report provides comprehensive insights about 35+ companies and 35+ pipeline drugs in Allergic Rhinitis pipeline landscape. It covers the Allergic Rhinitis pipeline drug profiles, including Allergic Rhinitis clinical trial and nonclinical stage products. It also covers the Allergic Rhinitis pipeline therapeutics assessment by product type, stage, route of administration, and molecule type. It further highlights the inactive pipeline products in this space.
Key takeaways from the Allergic Rhinitis Pipeline Report
Explore more about the latest breakthroughs of the Allergic Rhinitis treatment landscape @ Allergic Rhinitis Pipeline Outlook Report
Allergic Rhinitis Overview
Allergic rhinitis (AR) is an atopic disease presenting with symptoms of sneezing, nasal congestion, clear rhinorrhea, and nasal pruritis. It is an IgE-mediated immune response that is against inhaled antigens in the immediate phase, with a subsequent leukotriene-mediated late phase. It affects one in six individuals and is associated with significant morbidity, loss of productivity, and healthcare costs. Historically, Allergic rhinitis was thought to be a disease process of the nasal airway alone. Still, the development of the unified airway theory has classified AR as a component of systemic allergic response, with other associated conditions, such as asthma and atopic dermatitis, sharing an underlying systemic pathology. AR can be classified as either seasonal (intermittent) or perennial (chronic), with approximately 20% of cases being seasonal, 40% perennial, and 40% with features of both.
Recent Developmental Activities in the Allergic Rhinitis Treatment Landscape
Discover more information about allergic rhinitis emerging therapies and companies @ Allergic Rhinitis Treatment Landscape
Allergic Rhinitis Emerging Drugs
REGN5713-5714-5715: Regeneron Pharmaceuticals
REGN5713-5714-5715 is a cocktail of three Bet v1 monoclonal antibodies. Regeneron Pharmaceuticals is investigating REGN5713-5714-5715 as intravenous injections in Phase III clinical studies for the treatment of allergic rhinitis and conjunctivitis.
MM09-MG01:Immunotek
Inmunotek is developing a subcutaneously administered immunotherapy product MM 09, containing biological extracts of house dust mite, designated as M 601 (MM09-MG01). A Phase III Prospective, randomized, placebo-controlled, multicenter of 3 active treatment groups, compared to 1 placebo group, for the determination of the efficacy and safety of subcutaneous immunotherapy in patients with mild to moderate asthma and allergic rhinitis/rhinoconjunctivitis (intermittent or persistent) due to hypersensitivity to house dust mites (Dermatophagoides pteronyssinus and / or D. farinae) and grass pollen has been initiated.
Allergic Rhinitis Therapeutics Assessment
There are approx. 35+ key companies which are developing the therapies for Allergic Rhinitis. The companies which have their Allergic Rhinitis drug candidates in the mid to advanced stage, i.e. Phase III include, Regeneron Pharmaceuticals.
Learn more about the novel and emerging Allergic Rhinitis pipeline therapies @ Allergic Rhinitis Ongoing Clinical Trials Analysis
Scope of the Allergic Rhinitis Pipeline Report
Table of Content
To learn more information about the Key Allergic Rhinitis Companies and Drugs, just visit @ Allergic Rhinitis Market Drivers and Barriers
About Us
DelveInsight is a Business Consulting and Market research company, providing expert business solutions for the healthcare domain and offering quintessential advisory services in the areas of R&D, Strategy Formulation, Operations, Competitive Intelligence, Competitive Landscaping, and Mergers & Acquisitions.
Media ContactCompany Name: DelveInsight Business Research LLPContact Person: Yash BhardwajEmail: Send EmailPhone: 9193216187Address:304 S. Jones Blvd #2432City: Las VegasState: NVCountry: United StatesWebsite: https://www.delveinsight.com/